Replies to post #568881 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Fiction presented in the guise of fact.

[SkyLimit2022]

Wait for the advisory review.





https://www.raps.org/news-and-articles/news-articles/2023/2/top-fda-official-interested-in-project-orbis-for-c

https://www.fda.gov/drugs/news-events-human-drugs/50-years-progress-treating-patients-cancer



The PD1 combo study for recurrent GBM is really significant too. It has not gotten the publicity that it deserves since the exemplary P3 stole the spotlight when it was published in JAMA Oncology.

This whole video is awesome, but my favorite part is the brief mention of the pembrolizumab combo study at UCLA. Skip to about timestamp 6:30 of the video to hear Dr. Toms highlight the PD1 combo survival data!

https://clinicaltrials.gov/ct2/show/NCT04201873



Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials




https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020



https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter





https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/

[Roman516]

Based on your opinion?